Form 4: Theravance Biopharma CFO Sells Shares for Tax Obligations

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 18,627 ordinary shares to cover tax liabilities from vested restricted stock units.

Summary

• Aziz Sawaf, SVP & Chief Financial Officer of Theravance Biopharma US, LLC, reported a transaction involving ordinary shares of Theravance Biopharma, Inc.
• On November 20, 2025, 18,627 ordinary shares were disposed of at a price of $17.9 per share.
• This disposition was a withholding transaction with the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units, not an open market sale.
• Following this transaction, Aziz Sawaf beneficially owns 336,795 ordinary shares directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to executive compensation, neither inherently positive nor negative for the company's operational or financial performance.

Positives

• The transaction is a routine tax-related event, indicating the vesting of previously granted restricted stock units, which can be seen as a positive for executive compensation and retention.

Negatives

• A reduction in direct share ownership by a key executive, although for tax purposes, slightly decreases their direct stake in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends for biopharma.

Related Party Transactions

• The transaction involved the withholding of shares by the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations, which is a related party transaction between the company and its officer.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-open market transaction for tax purposes. It reflects the vesting of executive compensation.
• Employees: Reflects standard executive compensation practices, which can be a factor in employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary insider transaction for tax purposes related to executive compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as this filing alone does not alter the fundamental investment thesis.

Keywords

Theravance Biopharma, TBPH, Aziz Sawaf, Form 4, SEC filing, insider transaction, restricted stock units, tax withholding, executive compensation, share disposition